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The atomic coordinate of Cas9-sgRNA-dsDNA structure has been deposited in the Protein Data Bank with accession code 5F9R. The cryo-EM structures of guide RNA-bound Cas9 and target DNA-bound Cas9 have been deposited into the EMDataBank with accession codes EMD-3276 and EMD-3277, respectively. We thank G. Meigs, J. Holton (beamline 8.3.1 of the Advanced Light Source, Lawrence Berkeley National Laboratory) for assistance with data collection; Y. Cheng, R. Louder, S. Howes, E. Kellogg, R. Zhang, T. Houweling, Z. Yu, and M. J. de la Cruz for expert electron microscopy assistance; and members of the Doudna and Nogales laboratories for critical reading of the manuscript. F.J. is a Merck Fellow of the Damon Runyon Cancer Research Foundation (DRG-2201-14 Yongzhao Yan, 3 Neal Green, 4 Barbara Mroczkowski, 5 R. Jeffrey Neitz, 2 Peter Wipf, 3 Veronica Falconieri, 1 Raymond J. Deshaies, 6 Jacqueline L. S. Milne, 1 Donna Huryn, 3 Michelle Arkin, 2 Sriram Subramaniam 1 † p97 is a hexameric AAA+ adenosine triphosphatase (ATPase) that is an attractive target for cancer drug development. We report cryo-electron microscopy (cryo-EM) structures for adenosine diphosphate (ADP)-bound, full-length, hexameric wild-type p97 in the presence and absence of an allosteric inhibitor at resolutions of 2.3 and 2.4 angstroms, respectively. We also report cryo-EM structures (at resolutions of~3.3, 3.2, and 3.3 angstroms, respectively) for three distinct, coexisting functional states of p97 with occupancies of zero, one, or two molecules of adenosine 5′-O-(3-thiotriphosphate) (ATPgS) per protomer. A large corkscrew-like change in molecular architecture, coupled with upward displacement of the N-terminal domain, is observed only when ATPgS is bound to both the D1 and D2 domains of the protomer. These cryo-EM structures establish the sequence of nucleotide-driven structural changes in p97 at atomic resolution. They also enable elucidation of the binding mode of an allosteric small-molecule inhibitor to p97 and illustrate how inhibitor binding at the interface between the D1 and D2 domains prevents propagation of the conformational changes necessary for p97 function.
T he superfamily of AAA+ proteins (ATPases associated with diverse cellular activities) consists of molecular chaperones that serve major roles in cellular protein quality control; DNA replication, transcription, recombination, and repair; membrane fusion; movement of intracellular cargo; and cell cycle regulation (1, 2). These oligomeric ring-like enzymes, which typically form hexamers, contain common functional features including one or more conserved AAA+ ATPase cassettes in each protomer. These cassettes bind and hydrolyze ATP at the interface between adjacent subunits. The acquired energy from binding and catalysis of nucleotides induces a series of conformational changes to enable these enzymes to modulate their substrates. p97, a well-characterized member of this protein family, binds multiple proteins including deubiquitylating enzymes as well as ubiquitin-binding adaptors and ligases (3) (4) (5) (6) (7) . The central role that p97 plays in protein quality control makes it an attractive target for cancer chemotherapy, as disruption of both of these processes hinders cancer cell survival (8) . Up-regulation of p97 expression in cancer cells supports this premise (9) , as do reports of numerous structurally diverse inhibitor types (10) (11) (12) (13) (14) , including a potent inhibitor that entered a phase I clinical trial in 2015 (15) .
Structurally, each p97 protomer has a predicted molecular weight of~90 kDa and comprises an N-terminal domain (henceforth N domain), two tandem ATPase domains (designated D1 and D2) that pack as hexameric rings, and a short C-terminal domain. Structural studies of full-length p97 by x-ray crystallography have so far been limited to medium resolution (3.5 Å to 4.7 Å) (16), although higher-resolution structures of subcomplexes that contain D1 and the N domain or the D2 domain have revealed further architectural insights in these regions of the protein (16) (17) (18) (19) (20) . Determination of the atomic-resolution structure of native, full-length p97 in different conformational states and in complex with inhibitors is therefore of considerable biological and clinical interest.
Using cryo-EM, we first performed structural analysis of p97 without addition of exogenous nucleotides. This structure, determined at an overall resolution of 2.4 Å, shows the expected architecture of the hexameric complex ( fig. S1 , A and B). ADP occupies both the D1 and D2 domain nucleotide-binding pockets ( fig. S1 , C and D). Analysis of the conformational variants that emerge during three-dimensional classification suggests that subtle conformational heterogeneity in the ADP-bound D2 hexamer ( fig. S2 ) is a likely reason for the lower resolutions achieved in x-ray crystallographic analyses of full-length p97. Overall, the cryo-EM-derived structure of the D2 domain in the full-length hexamer is comparable to that determined for full-length p97 at 3.5 Å by x-ray crystallography, except for some differences in the relative disposition of the N domain (16) and better definition of the C-terminal a-helical subdomain that spans amino acid residues 645 to 763. Several classes of inhibitors, including those that act in an allosteric or competitive manner, have been identified that impair p97 ATPase activity (10) (11) (12) (13) (14) (21) (22) (23) (24) (25) (26) (27) . Determination of the cryo-EM structure at 2.3 Å resolution of p97 in complex with UPCDC30245, a phenyl indole derivative ( fig. S3 ) that is structurally related to a recently described series of allosteric inhibitors (14) , shows that this compound (half-maximal inhibitory concentratioñ 27 nM) binds at the junction between the D1 and D2 domains (Fig. 1, A and B) . A detailed view of the structure of a single p97 protomer shows the location of the inhibitor and bound ADP (Fig. 1 , C to E), including features such as the interaction of the ADP b-phosphate with a water molecule in the D1 domain ( Fig. 1D ) and hydrogen bonding of a water molecule to the a-phosphate moiety and to the hydroxyl group on the ribose ring proximal to the a-phosphate group (Fig. 1E) . Furthermore, the distal hydroxyl group of the ribose ring interacts with a water molecule hydrogen-bonded to the side-chain oxygen atom of Asn 660 and the main-chain carbonyl atom of residue Asp
478
. Local map resolution measured by ResMap (28) indicates that the density is weakest in the N domain, consistent with plots of B-factor profiles of the refined structure, which show that the average B-factor is highest in the N domain and in the D1-D2 connector region and lowest in the core of the D1 and D2 domains (Fig.  1, F and G, and fig. S4 ). The most ordered regions are at the p97 core, with a clear gradient toward higher B-factors at the periphery (movie S1).
Selected examples of the quality of the cryo-EM map in the D2 domain (residues 481 to 763) are presented in Fig. 2 , A to C. It is conceivable that the two discrete conformations of the Arg 599 side chain (Fig. 2B ) are relevant to the ability of p97 to locally adapt to structural variations in bound substrates because this residue has been implicated in substrate interactions in the pore region surrounded by the D2 hexamer. UPCDC30245 binding did not result in significant changes in conformation of the polypeptide backbone, including at the nucleotide-binding sites ( fig. S5 ). Visualization of density for the bound inhibitor in the map enabled determination of its conformation in the bound state and the local interactions involved in its binding at the D1-D2 interface. The inhibitor conformation is most ordered in the half that includes the indole ring that nestles into a binding pocket ( fig. S6A ). This inhibitorbinding site is sandwiched by the C-terminal regions of two a-helical segments that range from residues 483 to 498 and 523 to 534 (Fig. 2D) . The binding tunnel is capped at the end where the fluorinated indole ring is docked between two loop elements (amino acid residues 506 to 512 (D and E) Density maps for bound nucleotides, establishing that ADP is bound to both D1 and D2 domains, and visualization of densities for tightly bound water molecules (colored red, highlighted in yellow) at the nucleotide-binding sites. (F and G) Top and side views, respectively, of the structure (uncorrected density map), color-coded to represent variation in resolution across the protein as determined using ResMap (28) .
and 610 to 618) that lead into two parallel b strands. The other end of the binding cleft is open and solvent-exposed (Fig. 2, E and F) , with the piperazine ring of the inhibitor protruding outward into the bulk solvent. Residues that interact with ADP in the D1 and D2 sites are summarized in fig. S6 , B and C, respectively.
The key interactions that anchor the inhibitor arise from the main-chain carbonyl oxygen of have profound effects on activity, with both steric and electronic factors being important (14) . The interactions at the piperazine ring end are minimal, suggesting high conformational flexibility in this region, although the highly negatively charged outer surface of the binding tunnel ( fig.  S6A ) may enable better anchoring to the surface of p97. Mutagenesis studies have shown that the D1-D2 interface is important for p97 function (11, 12) and provide support for the structural studies we report here.
To unravel the intra-and interprotomer conformational changes that occur with ATP binding, we performed structural analysis of p97 in the presence of ATPgS at physiologically relevant concentrations. Earlier crystallographic studies of p97 with ATP analogs revealed only modest structural changes (16) , raising the concern that crystal packing constraints may have prevented capturing functionally relevant protein conformational changes. Cryo-EM methods have been applied previously to study p97 conformational changes; however, the resulting structures were at very low resolutions [~20 to 30 Å (29-31)] and did not result in definitive identification of the structural changes relative to the ADP-bound conformation. Here, we report separation of three well-defined, coexisting conformational states at near-atomic resolution (~3.2 to 3.3 Å) that are simultaneously populated when ATPgS is added to p97 (Fig. 3 and figs. S7 and S8) . In conformation I, ADP is bound in both D1 and D2 nucleotidebinding domains; in conformation II, ADP is bound in the D1 domain while ATPgS is bound in the D2 domain; and in conformation III, ATPgS is bound in the nucleotide-binding regions of both D1 and D2.
The differences in structure among the three states reveal an unambiguous and stepwise evolution of the conformational change with binding of ATPgS (Fig. 3, A to C) . Conformation II differs from I only at the D2 domain, while the N and D1 domains remain essentially unchanged (Fig. 3, D to F) . The changes in the D2 domain occur largely proximal to the nucleotide-binding region and result from the exchange of the bound ADP with ATPgS, as verified by direct visualization of density for the additional phosphate moiety in the binding site ( fig. S8 ). Within each protomer, there is a~10°to 15°rotational twist of the D2 domain with respect to the D1 domain, with the D1-D2 linker region serving as a hinge. This relative rotational displacement of the D2 ring with respect to the D1 ring is consistent with atomic force microscopy studies that have reported ATP-dependent rotation in p97 (32) .
The difference between conformation II and III is primarily in the N and D1 domains, with minimal changes in the D2 domain (Fig. 3, G to  I ). Here again, the change in conformation is directly associated with the exchange of ADP for ATPgS, with the density map demonstrating density for the additional phosphate moiety present in the D1 nucleotide-binding site ( fig. S8) . The most striking feature of this transition is the large-scale motion of the N domain away from the plane of the D1 hexamer. The structure of the N and D1 domains in conformation III is shown along with selected residues in its vicinity. There is strong density for the bound inhibitor for the segment encompassing the indole group to the piperidine ring and virtually no density at the other extremity, where the molecule is expected to be highly flexible because of minimal interactions with the protein.
essentially the same as that reported from x-ray crystallographic analysis of an isolated N-D1 fragment derived from a mutant p97 (33) . The changes include rearrangements at the peripheral helix in D1 and its interface with the D2 domain, and movement of the N domain from its original isoplanar or "down" position to an "up" position, where it is rotated by~75°and displaced by~14 Å. This out-of-plane conformation of the N-D1 domain and the double occupancy of both nucleotidebinding regions with ATPgS have not been reported in any of the full-length p97 structures solved by x-ray crystallography (16) . Additionally, the presence of ATPgS in conformations II and III results in the stabilization of the C-terminal helix of the D2 domain and extension of the traceable density from residue 763 to residue 768 ( fig. S8 , G to I). Our structural analyses thus show that the effect of ATPgS binding is a two-step, sequential conformational change in the D2 and D1 hexameric layers, respectively (Fig. 4A) . Analysis of the images without imposition of six-fold symmetry shows that the majority of the molecules are in one of the three conformations obtained with the use of symmetry, indicating that the structural differences among conformations I, II, and III are cooperative in nature ( fig. S9 ). The location of the inhibitor-binding site at the interface of domains D1 and D2 suggests that inhibitor binding prevents the nucleotide-driven conformational changes at the interface that are pivotal for p97 activity. To explore this further, we superimposed the structure of the p97-UPCDC30245 complex onto that of the ATPgS-bound p97 conformation II. The superposed models (Fig. 4B  and fig. S8J ) suggest that there would be steric clashes between the indole ring of the inhibitor and residues in the D2 loop (amino acid residues 611 to 616). Even if there is some flexibility in the D2 domain that enables some level of binding, key interactions that enable the binding of UPCDC30245 in the p97-ADP complex, such as that between the terminal fluorine atom and the backbone carbonyl Ser 511 (Fig. 2D) , cannot be achieved in the ATPgS-bound state. These observations indicate that UPCDC30245 is a conformation-selective inhibitor that preferentially binds the ADP state to act as a "wrench in the works."
The pivot-like movement of the D2 hexamer with ATPgS binding also affects pore dimensions (Fig. 4C) . Thus, with ATPgS binding, the diameter of the cytoplasmic face of the pore in the center of the D2 hexamer (measured by the a carbon of residue 755 in the 750-760 helix) contracts from 61 Å to~54 Å (movie S2), whereas the average outer (~28 Å) and inner (~6 Å) diameters of D1 are similar in the three conformations. Many of the residues that line the central pore are negatively charged and could be important in the context of binding of ubiquitylated substrates. The cavity at the center is large enough to accommodate substrates destined for degradation, but given that the changes in size with nucleotide binding are relatively small, our results are consistent with the suggestion (16) that substrates degraded by p97 may not be threaded through the central axis across the length of the barrel.
The ability to determine atomic-resolution structures for multiple conformational states that are present simultaneously in a dynamic molecular machine such as p97 is likely to be an increasingly common signature of the application of cryo-EM methods in structural biology. p97 mediates its function in the cell by interacting with a large array of effector proteins, most of which bind at the N domain, which undergoes a large movement with ATP binding, as our present work and previous structural studies demonstrate (5, 18, (34) (35) (36) . Cryo-EM studies could therefore be useful for a more detailed understanding of the structural basis of these interactions in normal cells and in diseases such as cancer. Further, the delineation of the inhibitor-bound p97 structure provides another example [besides b-galactosidase (37)] of a regulatory metabolic enzyme where cryo-EM at~2 Å resolution enables visualization of structural detail such as hydrogen-bonded water molecules, with features comparable to those seen in model-based 2F obs − F calc maps at similar reported resolutions obtained using x-ray crystallography ( fig. S10 ). The discovery of the specific mode of binding of a compound that blocks p97 activity provides new insights into the interactions and residues that are critical for function, and may enable the design of clinically useful inhibitors. 
